AR125400A1 - Compuestos de péptidos similares al glucagón - Google Patents
Compuestos de péptidos similares al glucagónInfo
- Publication number
- AR125400A1 AR125400A1 ARP220101035A ARP220101035A AR125400A1 AR 125400 A1 AR125400 A1 AR 125400A1 AR P220101035 A ARP220101035 A AR P220101035A AR P220101035 A ARP220101035 A AR P220101035A AR 125400 A1 AR125400 A1 AR 125400A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- disease
- diabetes
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 108010088406 Glucagon-Like Peptides Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229930195729 fatty acid Chemical class 0.000 abstract 2
- 239000000194 fatty acid Chemical class 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- -1 GLP-1 compound Chemical class 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 229940125898 compound 5 Drugs 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169757 | 2021-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125400A1 true AR125400A1 (es) | 2023-07-12 |
Family
ID=75639721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101035A AR125400A1 (es) | 2021-04-21 | 2022-04-21 | Compuestos de péptidos similares al glucagón |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240247042A1 (enExample) |
| EP (1) | EP4326330A1 (enExample) |
| JP (1) | JP2024514352A (enExample) |
| KR (1) | KR20230171471A (enExample) |
| CN (1) | CN117202936A (enExample) |
| AR (1) | AR125400A1 (enExample) |
| AU (1) | AU2022260805A1 (enExample) |
| BR (1) | BR112023021597A2 (enExample) |
| CA (1) | CA3216058A1 (enExample) |
| CL (1) | CL2023003091A1 (enExample) |
| IL (1) | IL307822A (enExample) |
| MX (1) | MX2023012290A (enExample) |
| TW (1) | TW202304500A (enExample) |
| WO (1) | WO2022224164A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221040A1 (es) | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| PL4271672T3 (pl) | 2021-04-21 | 2026-04-20 | Gilead Sciences, Inc. | Karboksybenzimidazolowe związki modulujące glp-1r |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3226906B1 (en) * | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| CA2972871A1 (en) * | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
-
2022
- 2022-04-19 TW TW111114875A patent/TW202304500A/zh unknown
- 2022-04-20 CN CN202280029619.8A patent/CN117202936A/zh active Pending
- 2022-04-20 KR KR1020237039490A patent/KR20230171471A/ko active Pending
- 2022-04-20 MX MX2023012290A patent/MX2023012290A/es unknown
- 2022-04-20 CA CA3216058A patent/CA3216058A1/en active Pending
- 2022-04-20 BR BR112023021597A patent/BR112023021597A2/pt unknown
- 2022-04-20 JP JP2023564257A patent/JP2024514352A/ja active Pending
- 2022-04-20 IL IL307822A patent/IL307822A/en unknown
- 2022-04-20 US US18/556,461 patent/US20240247042A1/en active Pending
- 2022-04-20 AU AU2022260805A patent/AU2022260805A1/en not_active Abandoned
- 2022-04-20 WO PCT/IB2022/053698 patent/WO2022224164A1/en not_active Ceased
- 2022-04-20 EP EP22719363.8A patent/EP4326330A1/en active Pending
- 2022-04-21 AR ARP220101035A patent/AR125400A1/es unknown
-
2023
- 2023-10-17 CL CL2023003091A patent/CL2023003091A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240247042A1 (en) | 2024-07-25 |
| WO2022224164A1 (en) | 2022-10-27 |
| CN117202936A (zh) | 2023-12-08 |
| IL307822A (en) | 2023-12-01 |
| CA3216058A1 (en) | 2022-10-27 |
| TW202304500A (zh) | 2023-02-01 |
| MX2023012290A (es) | 2023-10-26 |
| EP4326330A1 (en) | 2024-02-28 |
| JP2024514352A (ja) | 2024-04-01 |
| CL2023003091A1 (es) | 2024-05-03 |
| AU2022260805A1 (en) | 2023-10-19 |
| KR20230171471A (ko) | 2023-12-20 |
| BR112023021597A2 (pt) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17004665A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
| JP2023515404A5 (enExample) | ||
| JP2022512482A5 (enExample) | ||
| JP4397688B2 (ja) | 糖尿病またはレトロウイルス関連疾患の予防および治療用医薬の製造におけるスチルベン化合物の使用 | |
| JP5847533B2 (ja) | 新規甲状腺ホルモンβ受容体作動薬 | |
| CN107207483B (zh) | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 | |
| JP2009506094A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| CO6362003A2 (es) | Derivado de piridina | |
| JP2015517579A5 (enExample) | ||
| US20130324514A1 (en) | Indanyloxyphenylcyclopropanecarboxylic acids | |
| PT1633340E (pt) | Compostos para o tratamento de distúrbios metabólicos | |
| PE20211595A1 (es) | Compuestos de 2,6-diaminopiridina | |
| EP3573959A1 (en) | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | |
| CO2021016870A2 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| JP2018505158A5 (enExample) | ||
| JP2019532110A (ja) | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 | |
| US20230159551A1 (en) | Daphnane diterpenoid resistant to prostate cancer and preparation method thereof | |
| CN105982884B (zh) | 一种补骨脂二氢黄酮甲醚及其类似物的用途 | |
| CN101580510A (zh) | 青蒿素类衍生物及其应用 | |
| JP2009502777A5 (enExample) | ||
| TW201306830A (zh) | 用於治療糖尿病及新陳代謝疾病的組合物及其製備方法 | |
| KR101391905B1 (ko) | 물질대사 장애의 치료용 화합물 | |
| CN111718352B (zh) | 一类化合物及其药学上可接受的盐 | |
| MX2021011711A (es) | Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica. |